Article
Hematology
Kaito Harada, Shohei Mizuno, Shingo Yano, Akiyoshi Takami, Hiroto Ishii, Kazuhiro Ikegame, Yuho Najima, Shinichi Kako, Takashi Ashida, Souichi Shiratori, Shuichi Ota, Makoto Onizuka, Kentaro Fukushima, Takahiro Fukuda, Tatsuo Ichinohe, Yoshiko Atsuta, Masamitsu Yanada
Summary: Although haploidentical donor lymphocyte infusion (DLI) is a valid treatment option for relapsed acute myeloid leukemia (AML), the incidence and risk factors for graft-versus-host disease (GVHD) and the efficacy of haploidentical DLI have not been fully evaluated. Our retrospective analysis showed that a higher CD3(+) cell count was associated with an increased risk of acute GVHD, and preemptive DLI resulted in better overall response.
ANNALS OF HEMATOLOGY
(2022)
Article
Biochemistry & Molecular Biology
Antonella Mancusi, Francesco Zorutti, Loredana Ruggeri, Samanta Bonato, Sara Tricarico, Tiziana Zei, Roberta Iacucci Ostini, Valerio Viglione, Rebecca Sembenico, Sofia Sciabolacci, Valeria Cardinali, Massimo Fabrizio Martelli, Cristina Mecucci, Alessandra Carotti, Maria Paola Martelli, Andrea Velardi, Antonio Pierini
Summary: This study demonstrates the feasibility of using blinatumomab and DLI to treat relapses after Treg/Tcon haploidentical HSCT, and suggests that their preemptive use could improve efficacy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Immunology
Eva A. S. Koster, Edouard F. Bonneville, Peter A. von dem Borne, Peter van Balen, Erik W. A. Marijt, Jennifer M. L. Tjon, Tjeerd J. F. Snijders, Danielle van Lammeren, Hendrik Veelken, Hein Putter, J. H. Frederik Falkenburg, Constantijn J. M. Halkes, Liesbeth C. de Wreede
Summary: Alloreactive donor-derived T-cells play a crucial role in alloimmune responses after allogeneic hematopoietic stem cell transplantation (alloSCT), affecting both the prevention of leukemia relapse and the risk of graft-versus-host disease (GvHD). This study investigates the complex associations between T-cell kinetics and alloimmune responses in acute leukemia patients receiving alemtuzumab-based T-cell depletion alloSCT. The results demonstrate that donor lymphocyte infusion (DLI) can lead to detectable T-cell expansion, with CD4+ T-cells showing the strongest association with the development of alloimmune responses.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Oncology
Qiongqiong Su, Zhiping Fan, Fen Huang, Na Xu, Danian Nie, Dongjun Lin, Ziwen Guo, Pengcheng Shi, Zhixiang Wang, Ling Jiang, Jing Sun, Zujun Jiang, Qifa Liu, Li Xuan
Summary: Delaying prophylactic donor lymphocyte infusion (pDLI) to day +90 based on minimal residual disease (MRD) for patients with refractory/relapsed acute leukemia undergoing allo-HSCT could reduce extensive chronic GVHD incidence and improve GVHD-free/relapse-free survival (GRFS) without increasing the risk of leukemia relapse.
FRONTIERS IN ONCOLOGY
(2021)
Article
Oncology
Tingting Han, Yuqian Sun, Yang Liu, Chenhua Yan, Yu Wang, Lanping Xu, Kaiyan Liu, Xiaojun Huang, Xiaohui Zhang
Summary: This study retrospectively analyzed the efficacy of a second allogeneic hematopoietic stem cell transplantation (HSCT2) in 28 patients with relapsed/refractory acute leukemia after chemotherapy plus modified donor lymphocyte infusion following the first allo-HSCT (HSCT1). The findings showed a high rate of complete remission in patients post-HSCT2, with overall survival (OS) and disease-free survival (DFS) rates at 1 year post-HSCT2 being 25.0% and 21.4%, respectively. Risk factors for OS post-HSCT2 included risk stratification prior to HSCT1 and blast percentage before HSCT2, while relapse within 6 months post-HSCT1 was a risk factor for DFS and relapse post-HSCT2. The study suggests that HSCT2 could be a salvage option for patients with relapsed acute leukemia post-chemotherapy plus modified donor lymphocyte infusion.
FRONTIERS OF MEDICINE
(2021)
Article
Oncology
Katrin Teich, Michael Stadler, Razif Gabdoulline, Jyoti Kandarp, Clara Wienecke, Bennet Heida, Piroska Klement, Konstantin Buttner, Letizia Venturini, Martin Wichmann, Wolfram Puppe, Christian Schultze-Florey, Christian Koenecke, Gernot Beutel, Matthias Eder, Arnold Ganser, Michael Heuser, Felicitas Thol
Summary: Donor lymphocyte infusions (DLIs) can be used to prevent or treat relapse in acute myeloid leukemia (AML) patients after allogeneic hematopoietic cell transplantation (alloHCT). Measurable residual disease (MRD) is a valuable biomarker for predicting the response and outcome of DLI treatment. This retrospective study showed that MRD status before and after DLI treatment is prognostic for event-free survival, overall survival, cumulative incidence of relapse, and relapse-free survival.
Review
Immunology
Scott M. Krummey, Alison J. Gareau
Summary: Advances in hematopoietic stem cell transplant have led to changes in donor selection approach, including the use of haploidentical donors or permissive HLA mismatches. However, this may increase the risk of donor-specific HLA antibodies, which can limit engraftment. Desensitization treatments can effectively reduce HLA antibodies and improve transplant outcomes. The consideration and management of HLA antibodies in donor selection are increasingly important in HSCT.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Panagiotis Tsirigotis, Konstantinos Gkirkas, Vassiliki Kitsiou, Spiros Chondropoulos, Theofilos Athanassiades, Thomas Thomopoulos, Alexandra Tsirogianni, Maria Stamouli, Aggeliki Karagiannidi, Nikolaos Siafakas, Vassiliki Pappa, Arnon Nagler
Summary: The study demonstrates that prolonged up to three years of low-dose pro-DLI administered every two months is safe and effective in reducing relapse rate in patients with high-risk acute leukemia. The strategy of low-dose repetitive administration DLI reduces the risk of GVHD and helps in preventing relapse by inducing sustained immunological pressure on residual leukemic cells. Further testing in larger cohorts is warranted to confirm the efficacy of this novel approach in high-risk acute leukemia patients.
Article
Immunology
Hyery Kim, Beom Hee Lee, Hyo-Sang Do, Gu-Hwan Kim, Sunghan Kang, Kyung-Nam Koh, Ho Joon Im
Summary: Mevalonic aciduria (MA) is the most severe clinical subtype of mevalonate kinase deficiency (MKD) caused by an inherited defect in the mevalonate pathway. The treatment of MKD focuses on suppressing recurrent hyperinflammatory attacks using anti-inflammatory drugs. Allogeneic hematopoietic stem cell transplantation (HCT) has been shown to successfully ameliorate autoinflammatory attacks in patients with MKD who have MA.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Oncology
Xuefeng Li, Wen Wang, Xin Zhang, Yu Wu
Summary: The regimen of azacitidine and donor lymphocyte infusion (DLI) can safely improve the outcomes of relapsed acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), especially in patients with signs of early relapse. The administration of targeted medicines in azacitidine-based therapies may further improve the outcomes of relapsed AML/MDS.
FRONTIERS IN ONCOLOGY
(2022)
Article
Immunology
Zhihui Li, Fanqiao Meng, Jing Li, Tong Wu
Summary: This study reports the case of a patient with relapsed/refractory acute T-lymphocytic leukemia and hepatitis B who underwent donor-derived CD7 CAR-T therapy and allogeneic hematopoietic stem cell transplantation. The results show that this treatment approach not only achieved complete remission of T-ALL, but also effectively controlled hepatitis B virus.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Anna Soderstrom, Sofie Vonlanthen, Kerstin Jonsson-Videsater, Stephan Mielke, Hannes Lindahl, Johan Torlen, Michael Uhlin
Summary: This study found that measuring TREC levels can predict the prognosis of adult AML patients after bone marrow transplantation, especially overall survival. Lower TREC levels were associated with viral infections and CMV reactivation. KREC levels were not associated with clinical outcomes.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Hematology
Boris van der Zouwen, E. A. S. Koster, P. A. von dem Borne, L. E. M. Oosten, M. W. I. Roza-Scholten, T. J. F. Snijders, D. van Lammeren, P. van Balen, W. A. F. Marijt, H. Veelken, J. H. F. Falkenburg, L. C. de Wreede, C. J. M. Halkes
Summary: Prophylactic donor lymphocyte infusion (DLI) can introduce graft-versus-leukemia (GvL) effects with low risk of severe graft-versus-host-disease (GvHD) when initiated at 6 months after T cell-depleted allogeneic stem cell transplantation (TCD-alloSCT). This study retrospectively analyzed the use of low-dose early DLI at 3 months after alloSCT to prevent early relapse.
ANNALS OF HEMATOLOGY
(2023)
Review
Oncology
Li Xuan, Qifa Liu
Summary: Relapse is still the main reason for treatment failure in AML patients undergoing allo-HSCT. Evidence suggests that maintenance therapy post-transplantation, particularly targeted drugs like hypomethylating agents, FLT3 inhibitors, and isocitrate dehydrogenase inhibitors, could benefit AML patients, especially those at high risk.
JOURNAL OF HEMATOLOGY & ONCOLOGY
(2021)
Review
Cell & Tissue Engineering
Aiming Pang, Yingying Huo, Biao Shen, Yawei Zheng, Erlie Jiang, Sizhou Feng, Mingzhe Han
Summary: This study highlights the close relationship between clinical outcomes following ASCT and prognostic factors such as patient age, cytogenetic and molecular risk stratification, MRD status, as well as various measurements including pretransplant treatment, stem cell mobilization, collection, conditioning regimens, etc. Consequently, standardization of clinical practice for ASCT is necessary to further enhance patient outcomes.
STEM CELLS TRANSLATIONAL MEDICINE
(2021)
Meeting Abstract
Hematology
Gulsan Turkoz Sucak, Meral Bosnak Guclu, Zeynep Aribas, Gulsah Bargi, Elif Sakizli, Sahika Zeynep Aki, Zeynep Arzu Yegin
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
(2015)
Article
Oncology
Gulsah Bargi, Meral Bosnak Guclu, Zeynep Aribas, Sahika Zeynep Aki, Gulsan Turkoz Sucak
SUPPORTIVE CARE IN CANCER
(2016)
Article
Biophysics
S. Z. Aki, Y. Inamoto, P. A. Carpenter, B. E. Storer, B. M. Sandmaier, S. J. Lee, P. J. Martin, M. E. D. Flowers
BONE MARROW TRANSPLANTATION
(2016)
Article
Hematology
Nurdan Kokturk, Fatma Yildirim, Muge Aydogdu, Sahika Zeynep Aki, Zeynep Arzu Yegin, Zubeyde Nur Ozkurt, Elif Suyani, Ipek Kivilcim Oguzulgen, Gulsan Turkoz Sucak
TURKISH JOURNAL OF HEMATOLOGY
(2016)
Article
Transplantation
Serpil Muge Deger, Yasemin Erten, Elif Suyani, Sahika Zeynep Aki, Gulay Ulusal Okyay, Ozge T. Pasaoglu, Hatice Pasaoglu, Turgay Arinsoy, Gulsan Turkoz Sucak
EXPERIMENTAL AND CLINICAL TRANSPLANTATION
(2020)
Article
Virology
Veysel Sabri Hancer, Filiz Saglam Yarimcan, Murat Buyukdogan, Sahika Zeynep Aki, Burcu Oksuz, Kadir Acar, Muradiye Acar, Pelin Bulut
Article
Oncology
Eda Aypar, Fikret Vehbi Izzettin, Sahika Zeynep Aki, Mesut Sancar, Zeynep Arzu Yegin, Gulsan Turkoz-Sucak
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2018)
Article
Immunology
Sahika Zeynep Aki, Gulsan Turkoz Sucak, Ozlem Guzel Tunccan, Nurdan Kokturk, Esin Senol
TRANSPLANT INFECTIOUS DISEASE
(2018)
Article
Infectious Diseases
Diana Averbuch, Gloria Tridello, Jennifer Hoek, Malgorzata Mikulska, Thomas Pabst, Lucrecia Yanez San Segundo, Hamdi Akan, Tulay Ozcelik, Irene Donnini, Galina Klyasova, Aida Botelho de Sousa, Tsila Zuckerman, Cristina Tecchio, Rafael de la Camara, Sahika Zeynep Aki, Per Ljungman, Zafer Gulbas, Emmanuelle Nicolas-Virelizier, Elisabetta Calore, Katia Perruccio, Ron Ram, Claudio Annaloro, Rodrigo Martino, Batia Avni, Peter J. Shaw, Alexandra Jungova, Katia Codeluppi, Tracey O'Brien, Anna Waszczuk-Gajda, Montserrat Batlle, Anastasia Pouli, Catherina Lueck, Lidia Gil, Simona Iacobelli, Jan Styczynski, Dan Engelhard, Simone Cesaro
JOURNAL OF INFECTION
(2020)
Meeting Abstract
Biophysics
Diana Averbuch, Gloria Tridello, Jennifer Hoek, Malgorzata Mikulska, Thomas Pabst, Lucrecia Yanez San Segundo, Hamdi Akan, Tulay Ozcelik, Irene Donnini, Galina Klyasova, Aida Botelho de Sousa, Tsila Zuckerman, Depei Wu, Cristina Tecchio, Rafael de la Camara, Sahika Zeynep Aki, Per Ljungman, Zafer Gulbas, Emmanuelle Nicolas, Elisabetta Calore, Katia Perruccio, Ron Ram, Claudio Annaloro, Rodrigo Martino, Batia Avni, Peter Shaw, Lidia Gil, Simona Iacobelli, Jan Styczynski, Dan Engelhard, Simone Cesaro
BONE MARROW TRANSPLANTATION
(2018)
Meeting Abstract
Respiratory System
Gulsah Bargi, Meral Bosnak Guclu, Sahika Zeynep Aki, Gulsan Turkoz Sucak
EUROPEAN RESPIRATORY JOURNAL
(2017)
Meeting Abstract
Respiratory System
Gulsah Bargi, Meral Bosnak Guclu, Sahika Zeynep Aki, Gulsan Turkoz Sucak
EUROPEAN RESPIRATORY JOURNAL
(2017)
Article
Oncology
Zuebeyde Nur Ozkurt, Gulsan Tuerkoez Sucak, Sahika Zeynep Aki, Munci Yagci, Rauf Haznedar
CANCER INVESTIGATION
(2017)
Meeting Abstract
Pathology
B. Odut, S. Z. Aki, A. Armutlu, G. Sucak, U. Kocak, G. Esendagli, Z. Kaya, G. Akyol
Meeting Abstract
Biophysics
D. Averbuch, G. Tridello, J. Hoek, T. Pabst, T. Ozcelik, M. Mikulska, I. Donnini, G. Klyasova, D. Wu, L. Yanez San Segundo, T. Zuckerman, H. Akan, A. Botelho de Sousa, A. Xhaard, G. Salles, E. Calore, C. Tecchio, F. Patriarca, L. Cudillo, S. Zeynep Aki, R. Vrhovac, P. Ljungman, C. Annaloro, B. Avni, D. Engelhard, S. Cesaro
BONE MARROW TRANSPLANTATION
(2016)
